Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proximod in moderate-to-severe active rheumatoid arthritis
NCT07335952Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of proximod in rheumatoid arthritis (RA) (3 arms), sponsored by Peking University People's Hospital. Primary endpoint: American College of Rheumatology 20 response at 12 weeks. Started Sep 2024; status: completed.
02
Drugs
proximod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07335952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335952.